These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 21315278

  • 1. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
    Orcutt KD, Slusarczyk AL, Cieslewicz M, Ruiz-Yi B, Bhushan KR, Frangioni JV, Wittrup KD.
    Nucl Med Biol; 2011 Feb; 38(2):223-33. PubMed ID: 21315278
    [Abstract] [Full Text] [Related]

  • 2. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses.
    Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DB, Punzalan B, Pillarsetty NVK, Xu H, Guo HF, Monette S, Michel AO, Piersigilli A, Scheinberg DA, Ouerfelli O, Cheung NV, Larson SM.
    Theranostics; 2020 Feb; 10(25):11359-11375. PubMed ID: 33052220
    [Abstract] [Full Text] [Related]

  • 3. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
    Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA, O'Donoghue J, Smith-Jones PM, Wittrup KD, Cheung NV, Larson SM.
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK, Lee SG, Bell M, Singh M, Jungbluth AA, Zanzonico PB, Piersigilli A, Larson SM, Cheung NV.
    Theranostics; 2018 May; 8(18):5106-5125. PubMed ID: 30429889
    [Abstract] [Full Text] [Related]

  • 6. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
    Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NV, Larson SM.
    J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
    [Abstract] [Full Text] [Related]

  • 7. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
    Membreno R, Keinänen OM, Cook BE, Tully KM, Fung KC, Lewis JS, Zeglis BM.
    Mol Pharm; 2019 May 06; 16(5):2259-2263. PubMed ID: 30912951
    [Abstract] [Full Text] [Related]

  • 8. An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy.
    Cheal SM, Patel M, Yang G, Veach D, Xu H, Guo HF, Zanzonico PB, Axworthy DB, Cheung NV, Ouerfelli O, Larson SM.
    Bioconjug Chem; 2020 Mar 18; 31(3):501-506. PubMed ID: 31891487
    [Abstract] [Full Text] [Related]

  • 9. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.
    Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD.
    Mol Imaging Biol; 2011 Apr 18; 13(2):215-21. PubMed ID: 20533093
    [Abstract] [Full Text] [Related]

  • 10. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
    Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK.
    Mol Cancer Ther; 2014 Jul 18; 13(7):1803-12. PubMed ID: 24944121
    [Abstract] [Full Text] [Related]

  • 11. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody.
    Orcutt KD, Rhoden JJ, Ruiz-Yi B, Frangioni JV, Wittrup KD.
    Mol Cancer Ther; 2012 Jun 18; 11(6):1365-72. PubMed ID: 22491799
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, Renn O, Greiner DP, Kukis DL, Kronenberger SI.
    Cancer Res; 1994 Nov 15; 54(22):5937-46. PubMed ID: 7954426
    [Abstract] [Full Text] [Related]

  • 13. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
    Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW.
    Cancer Res; 2006 Apr 01; 66(7):3884-92. PubMed ID: 16585217
    [Abstract] [Full Text] [Related]

  • 14. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 15. Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT.
    DeNardo SJ, DeNardo GL, Brush J, Carter P.
    Hybridoma; 1999 Feb 05; 18(1):13-21. PubMed ID: 10211783
    [Abstract] [Full Text] [Related]

  • 16. Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging.
    Kim HY, Wang X, Wahlberg B, Edwards WB.
    Bioconjug Chem; 2014 Jul 16; 25(7):1311-22. PubMed ID: 24898150
    [Abstract] [Full Text] [Related]

  • 17. Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.
    Chandler CS, Bell MM, Chung SK, Veach DR, Fung EK, Punzalan B, Burnes Vargas D, Patel M, Xu H, Guo HF, Santich BH, Zanzonico PB, Monette S, Nash GM, Cercek A, Jungbluth A, Pandit-Taskar N, Cheung NKV, Larson SM, Cheal SM.
    Mol Cancer Ther; 2022 Jan 16; 21(1):125-137. PubMed ID: 34667111
    [Abstract] [Full Text] [Related]

  • 18. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging.
    Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA.
    J Nucl Med; 2008 Nov 16; 49(11):1828-35. PubMed ID: 18927335
    [Abstract] [Full Text] [Related]

  • 19. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, Goldenberg DM, Boerman OC.
    J Nucl Med; 2017 Jun 16; 58(6):926-933. PubMed ID: 28232604
    [Abstract] [Full Text] [Related]

  • 20. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy.
    DeNardo DG, Xiong CY, Shi XB, DeNardo GL, DeNardo SJ.
    Cancer Biother Radiopharm; 2001 Dec 16; 16(6):525-35. PubMed ID: 11789029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.